Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,207 total articles

Analysts Drive Datadog Rally as AI Demand and Upgrades Bolster Stock

Analysts Drive Datadog Rally as AI Demand and Upgrades Bolster Stock

Datadog shares jumped in pre-market trading after Truist Securities upgraded the stock to Buy and raised its price target to $300, citing strong fieldwork showing enterprise urgency around AI. BMO Capital also increased its target, and the company’s robust first-quarter 2026 results and updated guidance reinforced the bullish analyst momentum.

Doncasters Files for U.S. IPO, Seeking Up to $747 Million

Doncasters Files for U.S. IPO, Seeking Up to $747 Million

DPC Holdings Limited, trading as Doncasters, filed for an initial public offering in the United States to raise up to $747 million by selling 33,333,333 shares on the New York Stock Exchange. The proposed price range is $28 to $32 per share, which would value the company at more than $3.7 billion at the high end. The aerospace components maker repo…

U.S. Futures Jump After Washington-Tehran Accord; Micron, Nebius Lead Premarket Winners

U.S. Futures Jump After Washington-Tehran Accord; Micron, Nebius Lead Premarket Winners

U.S. index futures climbed sharply after Washington and Tehran confirmed a preliminary peace deal that could reopen critical Middle Eastern shipping lanes. The Nasdaq 100 led gains, with Micron, Nebius and several crypto-exposed stocks posting notable premarket moves. Traws Pharma plunged after a negative regulatory review forced a trial postponeme…

Global Drugmakers Accelerate U.S. Manufacturing and Inventory Moves as Tariff Threat Looms

Global Drugmakers Accelerate U.S. Manufacturing and Inventory Moves as Tariff Threat Looms

Faced with a proposed U.S. policy that would apply 100% tariffs to branded medicines unless producers lower prices or onshore production, multinational drugmakers have accelerated U.S. capital spending, stockpiling and operational changes. Some companies secured temporary exemptions through pricing commitments and platform participation, while othe…